3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
6
Glioblastoma
5
Esophageal Neoplasms
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Childhood Brain Neoplasm
2
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pancreatic carcinoma, familial
1
Pancreatic Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Neurodegenerative Diseases
1
Neoplasms
1
Malignant Solid Neoplasm
1
Lung Carcinoma Metastatic in the Brain
1
Kidney Neoplasms
1
Ischemic Stroke
1
Hypoxia
1
Interventions
Ifosfamide
5
Filgrastim
5
Doxorubicin
5
Gemcitabine
4
Docetaxel
4
Radiotherapy
3
Proton Therapy
3
Carboplatin
3
regorafenib
2
ivosidenib
2
enasidenib
2
belinostat
2
Sunitinib
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Immune Checkpoint Inhibitors
2
HhAntag691
2
Fluorouracil
2
Etoposide
2
Epirubicin
2
Cyclophosphamide
2
Cisplatin
2
Chemotherapy, Adjuvant
2
Celecoxib
2
Bevacizumab
2
venetoclax
1
toripalimab
1
temsirolimus
1
tanespimycin
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Chondrosarcoma
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts